CSBio CSBio

X
[{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Alhemo, the First Subcutaneous Prophylactic Treatment for People Living with Hemophilia B with Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Novo Nordisk"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Alhemo™ (concizumab) is the first anti-TFPI (Tissue Factor Pathway Inhibitor) approved by health canada for the treatment for people living with Hemophilia B in patients over the age of 12.

            Lead Product(s): Concizumab

            Therapeutic Area: Genetic Disease Product Name: Alhemo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY